Pfizer Inc. (NYSE:PFE) Shares Sold by VeraBank N.A.

VeraBank N.A. lowered its holdings in Pfizer Inc. (NYSE:PFE) by 4.6% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 35,048 shares of the biopharmaceutical company’s stock after selling 1,675 shares during the period. VeraBank N.A.’s holdings in Pfizer were worth $1,014,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. bought a new position in Pfizer in the 1st quarter worth about $315,000. GSA Capital Partners LLP bought a new stake in Pfizer during the 1st quarter valued at $439,000. Duality Advisers LP acquired a new position in Pfizer during the 1st quarter worth $1,009,000. Atomi Financial Group Inc. grew its stake in shares of Pfizer by 103.4% in the first quarter. Atomi Financial Group Inc. now owns 37,422 shares of the biopharmaceutical company’s stock worth $1,038,000 after purchasing an additional 19,024 shares in the last quarter. Finally, Stonebrook Private Inc. bought a new stake in shares of Pfizer during the first quarter valued at about $229,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Scott Gottlieb purchased 1,000 shares of the firm’s stock in a transaction on Wednesday, October 30th. The shares were bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.06% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. Wells Fargo & Company raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Finally, StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Eight equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $33.58.

Pfizer Stock Performance

PFE traded down $0.32 on Friday, hitting $26.72. The company had a trading volume of 55,951,315 shares, compared to its average volume of 37,583,031. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.60. The company’s fifty day moving average price is $28.89 and its 200 day moving average price is $28.63. The stock has a market cap of $151.42 billion, a price-to-earnings ratio of 36.11, a price-to-earnings-growth ratio of 0.87 and a beta of 0.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. During the same period last year, the business posted ($0.17) earnings per share. The firm’s revenue was up 31.2% compared to the same quarter last year. Equities analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a $0.42 dividend. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 6.29%. Pfizer’s payout ratio is 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.